BioCity Accelerator alumni, Convert Technologies, have been awarded funding by InnovateUK for a £500k project to build an asset tracking solution. The funding will enable the 12-18 months development project, called Range-IT, to start on 1st November 2020. Convert have received strategic support from Althea...
BioCity based Pharm2Farm (P2F) have developed a coating for textiles which incorporates its proprietary nanoparticles, to give textiles long-lasting virucidal properties. The first application of the technology was to coat a fabric layer in surgical masks and produce a certified antiviral, including Covid-19 and influenza, mask...
Released today by BioBeat, the seventh annual Movers and Shakers in BioBusiness report highlights 30 examples of resourceful leaders in the UK bioscience sector. The UK life sciences sector has risen to the challenges posed by COVID-19 with exceptional innovation and collaboration across industry, clinicians, the...
BioCity Glasgow based Roylance Pharma, a licensed outsourced controlled storage company dedicated to the life sciences, has partnered with Biocair to provide an end to end fully integrated outsourced storage solution for temperature-controlled pharmaceutical and biological materials. Biocair is a global specialist in life sciences logistics,...
MediCity Glasgow, a medical science business with the aim of generating £5 million has raised £26m and seen the creation of 201 new jobs. Since it was set up five years ago, MediCity Glasgow has helped create 70 new life science and med-tech companies The company supports...
BioCity Glasgow based ILC Therapeutics has announced that its unique synthetic Interferon called Alfacyte™ is fifteen to twenty times more effective at preventing the spread of SARS-CoV-2 (the virus which causes COVID-19) in cell culture than other commercially-available Interferons such as Interferon alpha 2 and...
Leading early-stage drug discovery, purification specialist and contract research organisation (CRO) Reach Separations has expanded its Nottingham premises in the wake of increased demand for its chiral purification services. Reach Separations specialises in chromatography for the analysis and purification of small molecules, and has added 1580...
BioCity Nottingham based Selentus Science Ltd is pleased to announce that its patent for TenaTac®, an innovative, adhesive surgical haemostat, has been allowed for grant in the UK, following an earlier grant in the USA. TenaTac is a Class III CE marked medical device that...
BioCity investee company, Deep Branch, has secured further investment to scale up the sustainable generation of protein that could transform food production and supply chains. Complementing the REACT-FIRST project, the company is turning industrial emissions into novel protein sources for animal feed and now, with European Innovation Council...
BiVictriX Therapeutics is pleased to announce the completion of a £1m funding round from existing shareholders, including Acceleris Private Investors, the Development Bank of Wales & BioCity Investments, alongside the Future Fund. The Future fund is a government convertible loan initiative set up to invest in...